MS at the Limits 2022 | Driving progress in progressive MS with multi-arm trials

There have been many studies in recent years which have assessed the potential of investigational agents to tackle progressive multiple sclerosis (MS), with numerous approaches showing promise for enhancing neuroprotection and remyelination. Jeremy Chataway, MA, PhD, FRCP, UCL Institute of Neurology, London, UK, believes that focusing on the progressive aspect of MS is key, as it is a substantial unmet therapeutic need. The Octopus multi-arm, multi-stage (MAMS) trial for progressive multiple sclerosis (MS) will simultaneously examine the safety and efficacy of 10 investigational/repurposed agents that show great potential. The multi-stage design means promising drugs can move through clinical development more quickly, while those that do not show strong early results can be dropped from the trial. The trial team considered between 40-50 agents for the trial, filtering down to their ‘top 10’ that will be further studied. This interview took place during the 2022 Multiple Sclerosis at the Limits Conference in London, UK.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.